American Society of Clinical Oncology

SHERPA: White

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. O'Reilly
    O'Reilly
  4. Saltz
    Saltz
  5. Bajorin
    Bajorin
  6. Kris
    Kris
  7. Hudis
    Hudis
  8. Morris
    Morris
  9. Rosenberg
    Rosenberg
  10. Robson
    Robson

Groups

  1. Department of Medicine (6399)
  2. Solid Tumor Oncology Division (5537)
  3. Survivorship Research (1997)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1637)
  6. Epidemiology and Biostatistics (1495)
  7. GSK Faculty (1389)
  8. Population Sciences Research Program (1379)
  9. Gastrointestinal Oncology Service (1353)
  10. Hematologic Malignancies, Division of (1281)
Search Within
Formats
  1. Meeting Abstract (6334)
  2. Journal Article (2579)
  3. Editorial (76)
  4. Review (68)
  5. Guidelines (54)
  6. Correspondence (49)
  7. Miscellaneous (4)
  8. Conference Paper (3)
Groups
  1. Department of Medicine (6399)
  2. Solid Tumor Oncology Division (5537)
  3. Survivorship Research (1997)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1637)
  6. Epidemiology and Biostatistics (1495)

More Groups

People
  1. Robert Motzer (451)
  2. Howard Scher (334)
  3. Eileen O'Reilly (306)
  4. Leonard Saltz (283)
  5. Dean Bajorin (280)
  6. Mark Kris (253)

More People

Years
  1. 2025 (275)
  2. 2024 (554)
  3. 2023 (580)
  4. 2022 (554)
  5. 2021 (504)
  6. 2020 (539)

More Years

Publications
  1. Journal of Clinical Oncology (8694)
  2. JCO Precision Oncology (171)
  3. Journal of Oncology Practice (124)
  4. American Society of Clinical Oncology Educational Book (112)
  5. JCO Clinical Cancer Informatics (53)
  6. JCO Oncology Practice (7)

More Publications

Results (9167)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of cisplatin (cis)-eligible population from EV-302/KEYNOTE-A39
    Meeting Abstract

    Bedke, J.; Van Der Heijden, M. S.; Powles, T.; Valderrama, B. P.; Kikuchi, E.; Iyer, G.; Vulsteke, C.; Swami, U.; Castellano, D.; Sarwar, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • irst-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses
    Meeting Abstract

    Juric, D.; Kalinsky, K.; Turner, N. C.; Jhaveri, K. L.; Schmid, P.; Loi, S.; Saura, C.; Im, S. A.; Sunpaweravong, P.; Li, H.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated overall survival analysis with 29-month follow-up of NAPOLI 3
    Meeting Abstract

    Hussein, M. A.; Khan, G.; Chandana, S. R.; Cid, R. A. P.; Kiss, I.; Gallego, J.; Macarulla, T.; De la Fouchardiere, C.; Goetze, T.; Dean, A. P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma
    Meeting Abstract

    Chan, S. L.; Sangro, B.; Kudo, M.; Erinjeri, J. P.; Qin, S.; Ren, Z.; Arai, Y.; Breder, V. V.; Lin, S. M.; Peron, J. M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study
    Meeting Abstract

    Pernas, S.; Im, S. A.; Hattori, M.; Xu, B.; Wang, S.; Lu, Y. S.; Borges, G.; Tsurutani, J.; Jhaveri, K. L.; Zhang, Q. Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis
    Meeting Abstract

    Rampal, R.; Grosicki, S.; Chraniuk, D.; Abruzzese, E.; Bose, P.; Gerds, A. T.; Vannucchi, A. M.; Palandri, F.; Lee, S. E.; Gupta, V.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of the cisplatin (cis)-ineligible population from EV-302/KEYNOTE-A39
    Meeting Abstract

    Van Der Heijden, M. S.; Gupta, S.; Bedke, J.; Valderrama, B. P.; Kikuchi, E.; Iyer, G.; Loriot, Y.; Dawson, N. A.; Hoffman-Censits, J. H.; Mar, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Evolution of tisagenlecleucel use for the treatment of pediatric and young adult relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL): Center for International Blood & Marrow Transplant Research (CIBMTR) registry results
    Meeting Abstract

    Rouce, R. H.; Baumeister, S. H. C.; Curran, K. J.; Fabrizio, V. A.; Hall, E. M.; Hsieh, E. M.; Karras, N. A.; Keating, A. K.; Moskop, A.; Pasquini, M. C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Seven-year overall survival analysis from ECHELON-1 study of A+ AVD versus ABVD in patients with previously untreated stage III/IV classical Hodgkin lymphoma
    Meeting Abstract

    Ansell, S. M.; Straus, D. J.; Connors, J. M.; Jurczak, W.; Kim, W. S.; Gallamini, A.; Ramchandren, R.; Friedberg, J. W.; Advani, R. H.; Hutchings, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)
    Meeting Abstract

    Garassino, M. C.; Wakelee, H. A.; Spicer, J.; Liberman, M.; Kato, T.; Tsuboi, M.; Lee, S. H.; Chen, K. N.; Dooms, C. A.; Majem, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save